» Articles » PMID: 26918545

An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women

Overview
Date 2016 Feb 27
PMID 26918545
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To develop and validate an HIV risk assessment tool to predict HIV acquisition among African women.

Design: Data were analyzed from 3 randomized trials of biomedical HIV prevention interventions among African women (VOICE, HPTN 035, and FEM-PrEP).

Methods: We implemented standard methods for the development of clinical prediction rules to generate a risk-scoring tool to predict HIV acquisition over the course of 1 year. Performance of the score was assessed through internal and external validations.

Results: The final risk score resulting from multivariable modeling included age, married/living with a partner, partner provides financial or material support, partner has other partners, alcohol use, detection of a curable sexually transmitted infection, and herpes simplex virus 2 serostatus. Point values for each factor ranged from 0 to 2, with a maximum possible total score of 11. Scores ≥5 were associated with HIV incidence >5 per 100 person-years and identified 91% of incident HIV infections from among only 64% of women. The area under the curve (AUC) for predictive ability of the score was 0.71 (95% confidence interval [CI]: 0.68 to 0.74), indicating good predictive ability. Risk score performance was generally similar with internal cross-validation (AUC = 0.69; 95% CI: 0.66 to 0.73) and external validation in HPTN 035 (AUC = 0.70; 95% CI: 0.65 to 0.75) and FEM-PrEP (AUC = 0.58; 95% CI: 0.51 to 0.65).

Conclusions: A discrete set of characteristics that can be easily assessed in clinical and research settings was predictive of HIV acquisition over 1 year. The use of a validated risk score could improve efficiency of recruitment into HIV prevention research and inform scale-up of HIV prevention strategies in women at highest risk.

Citing Articles

Preferences for HIV pre-exposure prophylaxis formulations and delivery among young African women: results of a discrete choice experiment.

Dlamini W, Mirembe B, Krows M, Peacock S, Kotze P, Selepe P J Int AIDS Soc. 2025; 28(2):e26422.

PMID: 39956930 PMC: 11830565. DOI: 10.1002/jia2.26422.


Review of Impact of Risk Reduction Sessions on Sexual Behaviors in HIV Prevention Trials: Insights from Africa.

Wand H, Reddy T, Moodley J, Naidoo S, Ramjee G Arch Sex Behav. 2025; 54(2):805-815.

PMID: 39806191 DOI: 10.1007/s10508-024-03052-8.


Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084.

Delany-Moretlwe S, Hanscom B, Guo X, Nkabiito C, Mandima P, Nahirya P J Int AIDS Soc. 2025; 28(1):e26401.

PMID: 39748218 PMC: 11695207. DOI: 10.1002/jia2.26401.


High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohort.

Gati Mirembe B, Donnell D, Krows M, Zwane Z, Bukusi E, Panchia R J Int AIDS Soc. 2024; 27(12):e26389.

PMID: 39653676 PMC: 11628190. DOI: 10.1002/jia2.26389.


HIV risk assessment tools for identifying individuals who could benefit from pre-exposure prophylaxis: a systematic review protocol.

Oo M, Shukalek C, Kishibe T, Hull M, Tan D BMJ Open. 2024; 14(11):e090565.

PMID: 39515851 PMC: 11552022. DOI: 10.1136/bmjopen-2024-090565.


References
1.
McCormack S, Ramjee G, Kamali A, Rees H, Crook A, Gafos M . PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010; 376(9749):1329-37. PMC: 2956883. DOI: 10.1016/S0140-6736(10)61086-0. View

2.
Baeten J, Nyange P, Richardson B, Lavreys L, Chohan B, Martin Jr H . Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol. 2001; 185(2):380-5. DOI: 10.1067/mob.2001.115862. View

3.
Buchbinder S, Glidden D, Liu A, McMahan V, Guanira J, Mayer K . HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis. 2014; 14(6):468-75. PMC: 4133171. DOI: 10.1016/S1473-3099(14)70025-8. View

4.
Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367(5):411-22. PMC: 3687217. DOI: 10.1056/NEJMoa1202614. View

5.
Kahle E, Hughes J, Lingappa J, John-Stewart G, Celum C, Nakku-Joloba E . An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2012; 62(3):339-47. PMC: 3620695. DOI: 10.1097/QAI.0b013e31827e622d. View